Therapeutic Asset Ratings

168 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Fludarabine Breast Carcinoma	Essen Biotech	P2	B (60)
Pembrolizumab Brain Cancer	Essen Biotech	P2	B (60)
Pembrolizumab Rectum Cancer	Essen Biotech	P2	B (60)
Fludarabine Bone Sarcoma	Essen Biotech	P2	B (59)
TIL Breast Cancer	Essen Biotech	P2	B (58)
Epirubicin Glioma	Essen Biotech	P2	B (57)
Fludarabine Sarcoma	Essen Biotech	P2	B (57)
Pembrolizumab Glioma	Essen Biotech	P2	B (57)
TIL Lung Cancer	Essen Biotech	P2	B (57)
Cyclophosphamide Kaposi Sarcoma	Essen Biotech	P1/2	B (57)
Pembrolizumab Liver Cancer	Essen Biotech	P2	CCC (55)
Fludarabine Brain Cancer	Essen Biotech	P1/2	CCC (55)
Fludarabine Ewing Sarcoma	Essen Biotech	P1/2	CCC (55)
Epirubicin Gliomas, Malignant	Essen Biotech	P1/2	CCC (54)
Pembrolizumab Gliomas, Malignant	Essen Biotech	P1/2	CCC (54)
Fludarabine Brain Tumor	Essen Biotech	P1/2	CCC (53)
Fludarabine Colon Cancer	Essen Biotech	P1/2	CCC (52)
Fludarabine Rectum Cancer	Essen Biotech	P1/2	CCC (50)
Pembrolizumab Glioma, Malignant	Essen Biotech	P1/2	CCC (50)
TIL Advanced Lung Cancer	Essen Biotech	P1/2	CCC (50)
TIL Brain Tumor	Essen Biotech	P1/2	CCC (50)
TIL Breast Carcinoma	Essen Biotech	P1/2	CCC (50)
Anti-Cd33 Cart AML, Adult Recurrent	Essen Biotech	P1/2	CCC (48)
Bcma/Gprc5D Car-T Cells Sarcoma, Ewing	Essen Biotech	P1/2	CCC (48)
Bcma/Gprc5D Car-T Cells Sarcoma, Kaposi	Essen Biotech	P1/2	CCC (48)

Showing 26 to 50 of 168 assets